Alexander Eustace


Contact Details

T:Ext. 7497

Assistant Professor
Profile Photo

Dr Eustace is a graduate of NUI Maynooth where he studied Biology and Chemistry.  He then undertook a MSc in Biological Sciences in Dublin City University.  Upon graduation Dr Eustace worked for a campus biotechnology company Archport Ltd, as a Downstream Process Technician/Manager.

in 2006 Dr Eustace returned to DCU to undertake his PhD in the field of Translational Oncology, graduating in 2010.  He then undertook several post-doctoral positions both in DCU and the Royal College of Surgeons in Ireland, working as part of the MTCI (SFI) and BreastPredict (Irish Cancer Society) funded research centres. 

In 2017 Dr Eustace returned to DCU as the research lead of Molecular Therapeutics for Cancer in ireland and more recently as Assistant Professor in the School of Biotechnology. 

Peer Reviewed Journal

Year Publication
2022 Mukherjee, N;Browne, A;Ivers, L;Santra, T;Cremona, M;Hennessy, BT;O'Donovan, N;Crown, J;Kolch, W;Fey, D;Eustace, AJ (2022) 'A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin'. Journal of personalized medicine, 12 (8). [DOI]
2022 Eustace, AJ;Lee, MJ;Colley, G;Roban, J;Downing, T;Buchanan, PJ (2022) 'Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer'. Cancer drug resistance (Alhambra, Calif.), 5 (3). [DOI]
2021 Collins DM;Madden SF;Gaynor N;AlSultan D;Le Gal M;Eustace AJ;Gately KA;Hughes C;Davies AM;Mahgoub T;Ballot J;Toomey S;O'Connor DP;Gallagher WM;Holmes FA;Espina V;Liotta L;Hennessy BT;O'Byrne KJ;Hasmann M;Bossenmaier B;O'Donovan N;Crown J; (2021) 'Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer'. Clinical Cancer Research, 27 (3). [DOI]
2021 Eustace, A.J.;Madden, S.F.;Fay, J.;Collins, D.M.;Kay, E.W.;Sheehan, K.M.;Furney, S.;Moran, B.;Fagan, A.;Morris, P.G.;Teiserskiene, A.;Hill, A.D.;Grogan, L.;Walshe, J.M.;Breathnach, O.;Power, C.;Duke, D.;Egan, K.;Gallagher, W.M.;O’Donovan, N.;Crown, J.;Toomey, S.;Hennessy, B.T. (2021) 'The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer'. Breast Cancer Research and Treatment, 187 . [Link] [DOI]
2020 Canonici A;Browne AL;Ibrahim MFK;Fanning KP;Roche S;Conlon NT;O'Neill F;Meiller J;Cremona M;Morgan C;Hennessy BT;Eustace AJ;Solca F;O'Donovan N;Crown J; (2020) 'Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer'. Therapeutic Advances in Medical Oncology, 12 . [DOI]
2020 Kennedy SP;O'Neill M;Cunningham D;Morris PG;Toomey S;Blanco-Aparicio C;Martinez S;Pastor J;Eustace AJ;Hennessy BT; (2020) 'Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer'. Oncogene, . [DOI]
2020 AlSultan, D;Kavanagh, E;O'Grady, S;Eustace, AJ;Castell, A;Larsson, LG;Crown, J;Madden, SF;Duffy, MJ (2020) 'The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells'. Investigational New Drugs, . [DOI]
2019 Gaule P;Mukherjee N;Corkery B;Eustace AJ;Gately K;Roche S;O'Connor R;O'Byrne KJ;Walsh N;Duffy MJ;Crown J;O'Donovan N; (2019) 'Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells'. Cancers, 11 (4). [DOI]
2019 Brown, P.;Zhou, Y.;Tan, A.C.;El-Esawi, M.A.;Liehr, T.;Blanck, O.;Gladue, D.P.;Almeida, G.M.F.;Cernava, T.;Sorzano, C.O.;Yeung, A.W.K.;Engel, M.S.;Chandrasekaran, A.R.;Muth, T.;Staege, M.S.;Daulatabad, S.V.;Widera, D.;Zhang, J.;Meule, A.;Honjo, K.;Pourret, O.;Yin, C.C.;Zhang, Z.;Cascella, M.;Flegel, W.A.;Goodyear, C.S.;van Raaij, M.J.;Bukowy-Bieryllo, Z.;Campana, L.G.;Kurniawan, N.A.;Lalaouna, D.;Hüttner, F.J.;Ammerman, B.A.;Ehret, F.;Cobine, P.A.;Tan, E.C.;Han, H.;Xia, W.;McCrum, C.;Dings, R.P.M.;Marinello, F.;Nilsson, H.;Nixon, B.;Voskarides, K.;Yang, L.;Costa, V.D.;Bengtsson-Palme, J.;Bradshaw, W.;Grimm, D.G.;Kumar, N.;Martis, E.;Prieto, D.;Sabnis, S.C.;Amer, S.E.D.R.;Liew, A.W.C.;Perco, P.;Rahimi, F.;Riva, G.;Zhang, C.;Devkota, H.P.;Ogami, K.;Basharat, Z.;Fierz, W.;Siebers, R.;Tan, K.H.;Boehme, K.A.;Brenneisen, P.;Brown, J.A.L.;Dalrymple, B.P.;Harvey, D.J.;Ng, G.;Werten, S.;Bleackley, M.;Dai, Z.;Dhariwal, R.;Gelfer, Y.;Hartmann, M.D.;Miotla, P.;Tamaian, R.;Govender, P.;Gurney-Champion, O.J.;Kauppila, J.H.;Zhang, X.;Echeverría, N.;Subhash, S.;Sallmon, H.;Tofani, M.;Bae, T.;Bosch, O.;Cuív, P.O.;Danchin, A.;Diouf, B.;Eerola, T.;Evangelou, E.;Filipp, F.;Klump, H.;Kurgan, L.;Smith, S.S.;Terrier, O.;Tuttle, N. (2019) 'Large expert-curated database for benchmarking document similarity detection in biomedical literature search'. Database, 2019 . [Link] [DOI]
2018 Elster N;Toomey S;Fan Y;Cremona M;Morgan C;Weiner Gorzel K;Bhreathnach U;Milewska M;Murphy M;Madden S;Naidoo J;Fay J;Kay E;Carr A;Kennedy S;Furney S;Mezynski J;Breathhnach O;Morris P;Grogan L;Hill A;Kennedy S;Crown J;Gallagher W;Hennessy B;Eustace A; (2018) 'Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer'. Therapeutic Advances in Medical Oncology, 10 . [DOI]
2018 Milewska M;Cremona M;Morgan C;O'Shea J;Carr A;Velanki SH;Hopkins AM;Toomey S;Madden SF;Hennessy BT;Eustace AJ; (2018) 'Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers'. Therapeutic Advances in Medical Oncology, 10 . [DOI]
2017 Toomey, S;Eustace, AJ;Fay, J;Sheehan, KM;Carr, A;Milewska, M;Madden, SF;Teiserskiene, A;Kay, EW;O'Donovan, N;Gallagher, W;Grogan, L;Breathnach, O;Walshe, J;Kelly, C;Moulton, B;Kennedy, MJ;Gullo, G;Hill, AD;Power, C;Duke, D;Hambly, N;Crown, J;Hennessy, BT (2017) 'Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies'. Breast Cancer Research, 19 . [DOI]
2017 O'Shea J;Cremona M;Morgan C;Milewska M;Holmes F;Espina V;Liotta L;O'Shaughnessy J;Toomey S;Madden SF;Carr A;Elster N;Hennessy BT;Eustace AJ; (2017) 'A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib'. Oncotarget, 8 (49). [DOI]
2016 Toomey S;Madden SF;Furney SJ;Fan Y;McCormack M;Stapleton C;Cremona M;Cavalleri GL;Milewska M;Elster N;Carr A;Fay J;Kay EW;Kennedy S;Crown J;Gallagher WM;Hennessy BT;Eustace AJ; (2016) 'The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer'. Oncotarget, 7 (46). [DOI]
2015 Elster N.;Collins D.;Toomey S.;Crown J.;Eustace A.;Hennessy B. (2015) 'HER2-family signalling mechanisms, clinical implications and targeting in breast cancer'. Breast Cancer Research and Treatment, 149 (1):5-15. [DOI]
2015 Mahgoub T.;Eustace A.;Collins D.;Walsh N.;O'Donovan N.;Crown J. (2015) 'Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma'. International Journal of Oncology, 47 (3):900-908. [DOI]
2015 Elster N;Cremona M;Morgan C;Toomey S;Carr A;O'Grady A;Hennessy BT;Eustace AJ; (2015) 'A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib'. Breast Cancer Research and Treatment, 149 (2). [DOI]
2014 Eustace A.;Kennedy S.;Larkin A.;Mahgoub T.;Tryfonopoulos D.;O'Driscoll L.;Clynes M.;Crown J.;O'Donovan N. (2014) 'Predictive biomarkers for dasatinib treatment in melanoma'. ONCOSCIENCE, 1 (2):158-166. [DOI]
2014 McDermott M.;Eustace A.;Busschots S.;Breen L.;Crown J.;Clynes M.;O'Donovan N.;Stordal B. (2014) 'In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: A practical guide with case studies'. Frontiers in Oncology, 4 MAR . [DOI]
2012 Browne B.;Eustace A.;Kennedy S.;O'Brien N.;Pedersen K.;McDermott M.;Larkin A.;Ballot J.;Mahgoub T.;Sclafani F.;Madden S.;Kennedy J.;Duffy M.;Crown J.;O'Donovan N. (2012) 'Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours'. Breast Cancer Research and Treatment, 136 (3):717-727. [DOI]
2011 Eustace A.;Dowling P.;Henry M.;Doolan P.;Meleady P.;Clynes M.;Crown J.;O'Donovan N. (2011) '2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines'. Journal of Proteomics, 74 (4):490-501. [DOI]
2011 Brougham D.;Ivanova G.;Gottschalk M.;Collins D.;Eustace A.;O'Connor R.;Havel J. (2011) 'Artificial neural networks for classification in metabolomic studies of whole cells using 1H Nuclear Magnetic Resonance'. Journal of Biomedicine and Biotechnology, 2011 . [DOI]
2010 Walsh N.;Kennedy S.;Larkin A.;Tryfonopoulos D.;Eustace A.;Mahgoub T.;Conway C.;Oglesby I.;Collins D.;Ballot J.;Ooi W.;Gullo G.;Clynes M.;Crown J.;O'Driscoll L. (2010) 'Membrane transport proteins in human melanoma: Associations with tumour aggressiveness and metastasis'. British Journal of Cancer, 102 (7):1157-1162. [DOI]
2008 Eustace, AJ;Crown, J;Clynes, M;O'Donovan, N (2008) 'Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines'. Journal of Translational Medicine, 6 . [DOI]
2008 Gottschalk M.;Ivanova G.;Collins D.;Eustace A.;O'Connor R.;Brougham D. (2008) 'Metabolomic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts'. NMR in Biomedicine, 21 (8):809-819. [DOI]
2008 Glynn, SA;O'Sullivan, D;Eustace, AJ;Clynes, M;O'Donovan, N (2008) 'The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells'. BMC Cancer, 8 . [DOI]
2008 Ivanova, GI;Cabrita, EJ;O'Connor, R;Eustace, AJ;Brougham, DF (2008) 'Application of diffusion-ordered spectroscopy for the analysis of cancer related biological samples'. Bulgarian Chemical Communications, 40 :464-468.

Review Articles

Year Publication
2010 Eustace, AJ;Mahgoub, T;Tryfonopoulos, D;O'Donovan, N;Crown, J (2010) Prospects for non-immunological molecular therapeutics in melanoma. ATHENS: REV

Conference Contribution

Year Publication
2022 Lisa Loughney, Aideen Scriney, Claire Timon, Pamela Gallagher, Denis M Collins, Alex Eustace, Jan Sorensen, Noel McCaffrey, Jurgen Mulsow, Lorraine Boran (2022) Irish Association for Cancer Research Annual Conference 2022 The PANO Trial: Physical Activity and Nutrition Optimisation Prehabilitation in Cancer Patients with Peritoneal Malignancy Cork, Ireland, .

Other Publication

Year Publication
2022 Kennedy, SP;Treacy, O;Allott, EH;Eustace, AJ;Lynam-Lennon, N;Buckley, N;Robson, T (2022) Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference. [DOI]
Certain data included herein are derived from the © Web of Science (2023) of Clarivate. All rights reserved.

Professional Associations

Association Function From / To
American Association for Cancer Research Associate Member -
American Society of Medical Oncologists Member -
Irish Association for Cancer Researchers Honorary Secretary -

Honors and Awards

Date Title Awarding Body
01/10/2016 RAMI St.Lukes Young Investigator award Royal Academy of Medicine Ireland


Employer Position From / To
Dublin City University Assistant Professor 01/09/2021 -
Royal College of Surgeons in ireland Research Fellow 03/09/2012 - 31/08/2017
Dublin City University Downstream Technician/Manager 01/11/2001 - 31/01/2003
Dublin City University Research Assistant 01/09/2004 - 30/11/2009
Dublin City University Research Lead Cancer Clinical Research Trust 01/09/2017 -
Dublin City University Post-Doctoral Scientist 01/12/2009 - 31/08/2012


Start date Institution Qualification Subject
15/09/1996 Maynooth NUI BSc Biology and Chemistry
18/09/2000 Dublin City University MSc Biological Sciences
12/09/2016 Royal College of Surgeons in Ireland Graduate Diploma Health Education
01/09/2006 Dublin City University PhD Translational Oncology

Research Interests

  • Translational Oncology
  • Genomic analysis of cancer to identify novel biomarkers of response and resistance to therapeutics
  • Drug repurposing to identify novel treatments for hard to treat cancers

Research Projects

Title Role Description Start date End date
IRC Enterprise partnership PhD studentship Supervisor 01/03/2019 28/02/2023
G-DEFINER Collaborator 01/02/2020 31/03/2023
Pancreatic Cancer Research Fund project award Collaborator 01/09/2019 31/08/2023
HRB Emerging Investigator Award Prinicpal investigator 01/12/2020 01/11/2024

Contract Researchers

Researcher Name Project Funding Body
Dr Rabab Kaneez HRB Emerging Investigators Award
Laura Ivers Cancer Clinical Research Trust
Anita White Cancer Clinical Research Trust

Current Postgraduate Students

Student Name Degree Supervision
Alsultan ,Dalal PhD Supervisor
Cuy Saques ,Arnau PhD Supervisor
Valenti ,Marta PhD-track Supervisor
Mcauley ,Lauren PhD-track Supervisor
Colley ,Grace PhD Supervisor

Modules Coordinated

Term Title Subject
2022 BE535
2022 BE333
2023 BE216
2023 BE116